Lentiviral CRISPR/Cas9 vector mediated miR-21 gene editing inhibits the epithelial to mesenchymal transition in ovarian cancer cells

被引:87
|
作者
Huo, Wenying [1 ,2 ,3 ,5 ,6 ]
Zhao, Guannan [1 ,2 ]
Yin, Jinggang [4 ]
Ouyang, Xuan [1 ,2 ]
Wang, Yinan [1 ,2 ]
Yang, Chuanhe [1 ,2 ]
Wang, Baojing [1 ,2 ]
Dong, Peixin [7 ]
Wang, Zhixiang [5 ]
Watari, Hidemichi [8 ]
Chaum, Edward [4 ]
Pfeffer, Lawrence M. [1 ,2 ]
Yue, Junming [1 ,2 ]
机构
[1] Univ Tennessee, Hlth Sci Ctr, Dept Pathol & Lab Med, Memphis, TN USA
[2] Univ Tennessee, Hlth Sci Ctr, Ctr Canc Res, Memphis, TN USA
[3] Univ Tennessee, Hlth Sci Ctr, Dept Physiol, Memphis, TN USA
[4] Univ Tennessee, Hlth Sci Ctr, Dept Ophthalmol, Memphis, TN USA
[5] Henan Agr Univ, Zhengzhou, Peoples R China
[6] Henan Univ Anim Husb & Econ, Zhengzhou, Peoples R China
[7] Hokkaido Univ, Dept Womens Hlth Educ Syst, Sch Med, Sapporo, Hokkaido, Japan
[8] Hokkaido Univ, Sch Med, Dept Gynecol, Sapporo, Hokkaido, Japan
来源
JOURNAL OF CANCER | 2017年 / 8卷 / 01期
关键词
miR-21; CRISPR/Cas9; lentiviral vector; ovarian cancer; EMT; COLON-CANCER; EXPRESSION; APOPTOSIS; PATHWAY; EMT;
D O I
10.7150/jca.16723
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats) mediated genome editing is a powerful approach for loss of function studies. Here we report that lentiviral CRISPR/Cas9 vectors are highly efficient in introducing mutations in the precursor miRNA sequence, thus leading to the loss of miRNA expression and function. We constructed four different lentiviral CRISPR/Cas9 vectors that target different regions of the precursor miR-21 sequence and found that these lentiviral CRISPR/Cas9 miR-21 gRNA vectors induced mutations in the precursor sequences as shown by DNA surveyor mutation assay and Sanger sequencing. Two miR-21 lentiviral CRISPR/Cas9 gRNA vectors were selected to probe miR-21 function in ovarian cancer SKOV3 and OVCAR3 cell lines. Our data demonstrate that disruption of pre-miR-21 sequences leads to reduced cell proliferation, migration and invasion. Moreover, CRISPR/Cas9-mediated miR-21 gene editing sensitizes both SKOV3 and OVCAR3 cells to chemotherapeutic drug treatment. Disruption of miR-21 leads to the inhibition of epithelial to mesenchymal transition (EMT) in both SKOV3 and OVCAR3 cells as evidenced by the upregulation of epithelial cell marker E-cadherin and downregulation of mesenchymal marker genes, vimentin and Snai2. The miR-21 target genes PDCD4 and SPRY2 were upregulated in cells transduced with miR-21gRNAs compared to controls. Our study indicates that lentiviral CRISPR/Cas9-mediated miRNA gene editing is an effective approach to address miRNA function, and disruption of miR-21 inhibits EMT in ovarian cancer cells.
引用
收藏
页码:57 / 64
页数:8
相关论文
共 50 条
  • [41] Differentiation of human umbilical cord mesenchymal stem cells into parathyroid cells by editing the PTH gene with the CRISPR/Cas9 system
    Zhang, Huiting
    Zhang, Yiting
    Qiu, Changhong
    Zhu, Wentian
    Wen, Mingbo
    Lao, Xuejun
    BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT, 2021, 35 (01) : 1207 - 1213
  • [42] Multiplexed CRISPR gene editing in primary human islet cells with Cas9 ribonucleoprotein
    Bevacqua, Romina J.
    Zhao, Weichen
    Merheb, Emilio
    Kim, Seung Hyun
    Marson, Alexander
    Gloyn, Anna L.
    Kim, Seung K.
    ISCIENCE, 2024, 27 (01)
  • [43] CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer
    Vaghari-Tabari, Mostafa
    Hassanpour, Parisa
    Sadeghsoltani, Fatemeh
    Malakoti, Faezeh
    Alemi, Forough
    Qujeq, Durdi
    Asemi, Zatollah
    Yousefi, Bahman
    CELLULAR & MOLECULAR BIOLOGY LETTERS, 2022, 27 (01)
  • [44] Efficient Genome Editing in Mammalian Cells Using a CRISPR/Cas9 Hybrid Baculoviral Vector
    Sung, Li-Yu
    Hu, Yu-Chen
    MOLECULAR THERAPY, 2014, 22 : S39 - S39
  • [45] Prospects and challenges of CRISPR/Cas9 gene-editing technology in cancer research
    Ning, Li
    Xi, Jiahui
    Zi, Yin
    Chen, Min
    Zou, Qingjian
    Zhou, Xiaoqing
    Tang, Chengcheng
    CLINICAL GENETICS, 2023, 104 (06) : 613 - 624
  • [46] Development of intraocular gene editing in mice following subretinal injection of CRISPR/Cas9 expressing lentiviral particles
    Holmgaard, A.
    Askou, A. L.
    Mikkelsen, G.
    Corydon, T. J.
    HUMAN GENE THERAPY, 2016, 27 (11) : A122 - A122
  • [47] CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer
    Mostafa Vaghari-Tabari
    Parisa Hassanpour
    Fatemeh Sadeghsoltani
    Faezeh Malakoti
    Forough Alemi
    Durdi Qujeq
    Zatollah Asemi
    Bahman Yousefi
    Cellular & Molecular Biology Letters, 2022, 27
  • [48] CRISPR/Cas9-Mediated Gene Editing in Human Airway Cells
    Yan, Ziying
    Feng, Zehua
    Park, Soo Yuen
    Vorhies, Kai
    Rotti, Pavana Gururaj
    Engelhardt, John F.
    MOLECULAR THERAPY, 2020, 28 (04) : 107 - 108
  • [49] SPTBN1 inhibits growth and epithelial-mesenchymal transition in breast cancer by downregulating miR-21
    Wu, Huijie
    Chen, Shuyi
    Liu, Chenyang
    Li, Jiajia
    Wei, Xiangxiang
    Jia, Mengping
    Guo, Jieyu
    Jin, Jiayu
    Meng, Dan
    Zhi, Xiuling
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 909
  • [50] Evaluation of CRISPR/Cas9 mediated TGIF gene editing to inhibit corneal fibrosis in vitro
    Tripathi, Ratnakar
    Sinha, Nishant R.
    Kempuraj, Duraisamy
    Balne, Praveen K.
    Landreneau, James R.
    Juneja, Ankit
    Webel, Aaron D.
    Mohan, Rajiv R.
    EXPERIMENTAL EYE RESEARCH, 2022, 220